SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus (Q39189383)

9 September 2017

SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus (English)

1 reference

9 September 2017

1 reference

Jayant Dey

1

1 reference

PubMed ID

28322073

9 September 2017

language of work or name

English

0 references

publication date

21 March 2017

1 reference

9 September 2017

Postgraduate Medicine

1 reference

9 September 2017

129

1 reference

9 September 2017

409-420

1 reference

9 September 2017

4

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

9 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00325481.2017.1307081

10.1080/00325481.2017.1307081

21 January 2018

Identifiers

DOI

1 reference

release_s377yrfy3jht5obrrdf4sadppy

9 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/s377yrfy3jht5obrrdf4sadppy

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

28322073

1 reference

PubMed ID

28322073